MARS BIOIMAGING

Revolutionising medical imaging and patient care



Investment highlights and opportunity:

MARS brings breakthrough imaging technology into the healthcare sector:

Strong IP portfolio and partnerships	NZ Clinical trials on hand and wrists completed
>$10m research scanner sales achieved	Signed agreement with the number one surgical hospital in the US

Series A Capital Rise – Lead secured @ $4.5m

NZD $12-15 million

Use of funds:

- Finalise FDA and MDSAP compliance
- Human capital development
- Marketing & sales channel expansion
- Scale production and supply chain support

Problem:

Diagnostic Imaging Systemic Failings:

- Lack of high-quality diagnostic imaging at the point of care
- Results in long care pathway
- High cost to health providers and patients
- Multiplicity/complexity of diagnostic tools

Solution:

MARS Extremity Scanners:

Our images transverse the healthcare pathway utilising a solid-state photon counting detector that is based on Medipix technology, developed at CERN.

- **HIGHER THROUGHPUT** across the health system including hospitals, clinics and surgeries
- **HIGHER QUALITY, LOWER COST PER IMAGE** for all stakeholders: public, private, insurers, patients.
- **LOWER CAPITAL** and operating costs for public and private care providers**. SMALLER FOOTPRINT**, easy to operate, at the point of care.
- **BEST-IN-CLASS** pre-and-post-operative CT diagnostic imaging early in the care pathway.

- MARS scan of a wrist with a scaphoid fracture

- Standard cone beam CT scan of the same patient

Market opportunity:

The Global 'Point of Care' imaging market is forecast to increase from USD$500m in 2024 to USD$870m in 2027

Point of Care scanners do not require the costly physical infrastructure associated with traditional CT and MRI machines - reducing costs to the health system while improving patient outcomes.

The MARS Imaging System is designed for use at the Point of Care, making it ideal for the increasing demands of the diagnostic imaging landscape.

Collaborators and partners:

Novel Technology

MARS holds the global medical license for CERN developed, Medipix technology.

MARS develops and produces MBI Extremity Scanners using a combination of soft IP, patented technologies and in house expertise.

MARS collaborates with key worldwide cornerstone partners on their path to commercialisation and global sales.

Go-to-market

Direct and radiology/clinical partner sales.

Key markets: US/Canada, New Zealand/Australia, UK/Europe, Japan markets

Current market segments: Orthopaedics and Rheumatology

Future market opportunities: Dentistry and Musculoskeletal

Executive Team:

Mark Figgitt – CEO
Experienced leading growth for health software cardiology and radiology providers

Rob Campbell – CFO
Chartered director and executive management professional

Professor Anthony Butler
Co-founder, CMO and Executive Director Clinical radiologist and Head of Radiology at the University of Otago.

Financials: